Analyse Roche Holding AG

Fundamentele Analyse FY 2017


Fundamentele Analyse FY 2016

Dr Severin Schwan Chief Executive Officer commented : 

 

"In 2016, we achieved all our  nancial targets. Pharmaceuticals sales were up 3%*. Diagnostics sales even increased by 7%—again well above market growth. Roche’s business success is re ected not least in the core earnings per share and non-voting equity security, which increased 5%.

  In 2017 we expect a number of key clinical study results and product approvals, and overall we anticipate sales to grow low- to mid-single digit, at constant exchange rates. We are also aiming for core earnings per share to grow broadly in line with sales, at constant exchange rates. And we are planning to further increase the dividend in Swiss francs for 2017.

  Roche is strongly positioned for the future. We are the world’s largest biotech company, the leader in cancer therapy, equipped with one of the best product pipelines in the industry and the number 1 in laboratory diagnostics. I am con dent that Roche will continue its 120-year success story."

 

Source : Roche AG, Annual Report 2016, London 1 February 2017.